We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly
Read MoreHide Full Article
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , is a global healthcare company with core products in a number of primary-care pharmaceutical markets. Lilly generates revenues from its pharmaceutical product and animal health segments.
The company’s portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Cialis (erectile dysfunction), Strattera (attention deficit hyperactivity disorder - ADHD), Erbitux (cancer) and Alimta (chemotherapy). Lilly also has a strong presence in the diabetes market. However, many of its key products like Cymbalta and Alimta are facing generic competition. The company also has some new products like Trulicity, Cyramza and Taltz in its portfolio which have started contributing to revenues.
Lilly’s earnings performance has been rather poor with earnings missing expectations in three of the last four quarters, while beating in only one, bringing the average negative surprise to 3.39%.
Currently, Lilly has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Lilly beat on first quarter earnings. The company reported EPS of 98 cents while our consensus called for EPS of 96 cents.
Revenues Miss: Revenues, however, were slightly below expectations. Lilly posted revenues of $5.23 billion, compared to our consensus estimate of $5.26 billion.
2017 Outlook: Lilly maintained its previously issued adjusted 2017 outlook. Adjusted earnings per share are expected in the range of $4.05 to $4.15, representing a growth rate of 15% to 18%. Revenues are expected in the range of $21.8–$22.3 billion. The Zacks Consensus Estimate for earnings and revenues is $4.11 per share and $22.14 billion, respectively.
Stock Price Impact: Shares were in-active in pre-market trading.
Check back later for our full write up on this Lilly earnings report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , is a global healthcare company with core products in a number of primary-care pharmaceutical markets. Lilly generates revenues from its pharmaceutical product and animal health segments.
The company’s portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Cialis (erectile dysfunction), Strattera (attention deficit hyperactivity disorder - ADHD), Erbitux (cancer) and Alimta (chemotherapy). Lilly also has a strong presence in the diabetes market. However, many of its key products like Cymbalta and Alimta are facing generic competition. The company also has some new products like Trulicity, Cyramza and Taltz in its portfolio which have started contributing to revenues.
Lilly’s earnings performance has been rather poor with earnings missing expectations in three of the last four quarters, while beating in only one, bringing the average negative surprise to 3.39%.
Currently, Lilly has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Lilly beat on first quarter earnings. The company reported EPS of 98 cents while our consensus called for EPS of 96 cents.
Revenues Miss: Revenues, however, were slightly below expectations. Lilly posted revenues of $5.23 billion, compared to our consensus estimate of $5.26 billion.
2017 Outlook: Lilly maintained its previously issued adjusted 2017 outlook. Adjusted earnings per share are expected in the range of $4.05 to $4.15, representing a growth rate of 15% to 18%. Revenues are expected in the range of $21.8–$22.3 billion. The Zacks Consensus Estimate for earnings and revenues is $4.11 per share and $22.14 billion, respectively.
Stock Price Impact: Shares were in-active in pre-market trading.
Eli Lilly and Company Price and EPS Surprise
Eli Lilly and Company Price and EPS Surprise | Eli Lilly and Company Quote
Check back later for our full write up on this Lilly earnings report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>